当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2020-04-28 , DOI: 10.1021/acs.jmedchem.0c00107
Olga Balabon 1, 2 , Eleni Pitta 1, 2 , Maciej K Rogacki 1, 2 , Eugenia Meiler 2 , Ruth Casanueva 2 , Laura Guijarro 2 , Sophie Huss 2 , Eva Maria Lopez-Roman 2 , Ángel Santos-Villarejo 2 , Koen Augustyns 1 , Lluis Ballell 2 , David Barros Aguirre 2 , Robert H Bates 2 , Fraser Cunningham 2 , Monica Cacho 2 , Pieter Van der Veken 1
Affiliation  

In search of novel drugs against tuberculosis, we previously discovered and profiled a novel hydantoin-based family that demonstrated highly promising in vitro potency against Mycobacterium. tuberculosis. The compounds were found to be noncovalent inhibitors of DprE1, a subunit of decaprenylphosphoryl-β-d-ribose-2'-epimerase. This protein, localized in the periplasmic space of the mycobacterial cell wall, was shown to be an essential and vulnerable antimycobacterial drug target. Here, we report the further SAR exploration of this chemical family through more than 80 new analogues. Among these, the most active representatives combined submicromolar cellular potency and nanomolar target affinity with balanced physicochemical properties and low human cytotoxicity. Moreover, we demonstrate in vivo activity in an acute Mtb infection model and provide further proof of DprE1 being the target of the hydantoins. Overall, the hydantoin family of DprE1 inhibitors represents a promising noncovalent lead series for the discovery of novel antituberculosis agents.

中文翻译:

乙内酰脲的优化作为有效的抗分枝杆菌癸烯酰基磷酸基-β-d-核糖氧化酶(DprE1)抑制剂。

为了寻找抗结核的新药,我们先前发现并分析了一个基于乙内酰脲的新型家族,该家族在体外对分枝杆菌有极高的潜力。结核。发现这些化合物是DprE1的非共价抑制剂,DprE1是癸二烯基磷酸基-β-d-核糖-2'-表异构酶的亚基。该蛋白位于分枝杆菌细胞壁的周质空间中,被证明是一种必不可少的易受感染的分枝杆菌药物靶标。在这里,我们报告了通过80多个新类似物对该化学家族进行的SAR进一步探索。在这些中,最活跃的代表结合了亚微摩尔细胞效价和纳摩尔靶标亲和力以及平衡的理化特性和较低的人类细胞毒性。此外,我们证明了在急性Mtb感染模型中的体内活性,并提供了DprE1作为乙内酰脲靶标的进一步证据。总体而言,DprE1抑制剂的乙内酰脲家族代表了发现新型抗结核药的有前途的非共价先导系列。
更新日期:2020-04-28
down
wechat
bug